Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
Daniel A PollyeaCourtney D D DiNardoMartha L ArellanoArnaud PigneuxWalter FiedlerMarina KonoplevaDavid A RizzieriB Douglas SmithAtsushi ShinagawaRoberto M LemoliMonique DailYinghui DuanBrenda J ChylaJalaja PotluriCatherine L MillerHagop M KantarjianPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Patients with IDH1/2mut who received venetoclax + azacitidine had high response rates, durable remissions, and significant OS; cytogenetic risk did not mitigate the favorable outcomes seen from this regimen for IDH1/2mut. See related commentary by Perl and Vyas, p. 2719.